From: Selecting the optimal position of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer – the SONIA study: study protocol for a randomized controlled trial
Grade 3
HR ≤0.65 and gain ≥3 months
Grade 2
HR ≤0.65 but gain < 3 months
Grade 1
HR > 0.65